Advertisement - Members don't see this ad
WASHINGTON – Today, the U.S. Drug Enforcement Administration filed its intent to temporarily place 7-hydroxymitagynine (7-OH) and three related substances into Schedule I of the Controlled Substances Act (CSA). Prior to DEA issuing this notice, the Department of Health and Human Services (HHS) confirmed synthetic 7-OH, and the three related substances have no accepted medical use and a high potential for abuse.
This temporary scheduling action does not apply to botanical kratom products that contain naturally occurring 7-OH below the specified threshold. Instead, it targets synthesized products and those containing elevated concentrations of 7-OH as outlined in the temporary scheduling order. DEA believes these substances pose an imminent threat to public safety given their effects are highly unpredictable.
The United States has seen a proliferation of commercial products containing semi-synthetic 7-OH. These products are widely marketed online and sold in gas stations, convenience stores, and smoke shops in a variety of forms, including powders, tablets, capsules, gummies, and dissolvable strips. DEA laboratory findings indicate commercial products often contain higher amounts of 7-OH than what is found in natural-occurring, botanical kratom.
